Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 1/7/2020
SIETES contiene 93059 citas

 1 a 20 de 84 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
2. Cita con resumen
Anónimo. Atteintes des ongles d'origine médicamenteuse. Prescrire 2014;34:191-4. [Ref.ID 97362]
3. Cita con resumen
Rutherford GW. Antiretroviral therapy and sexually transmitted HIV infection. BMJ 2012;344:9. [Ref.ID 92609]
4. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
5. Cita con resumen
Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, de Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-30. [Ref.ID 87818]
Gross R, Tierney C, Andrade A, Lamala C, Rosenkranz S, Eshleman SH, Flamigan T, Santana J, Salomon N, Reisler R, Wiggins I, Hogg E, Flexner C, Mildvan D, for the AIDS Clinical Trials Group A5073 Study Team. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-Naïve HIV-1-infected patients. A randomized trial. Arch Intern Med 2009;169:1224-32. [Ref.ID 86336]
7. Cita con resumen
Roca B. Farmacogenómica de los antirretrovirales. Med Clin (Barc) 2009;132:268-71. [Ref.ID 85491]
Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:288-92. [Ref.ID 85162]
10.Tiene citas relacionadas Cita con resumen
Cutrell A, Brothers C, Yeo J, Hernández J, Lapierre D. Abacavir and the potential risk of myocardial infarction. Lancet 2008;371:1413. [Ref.ID 82736]
11.Tiene citas relacionadas
Stein JH, Currier JS. Risk of myocardial infarction and nucleoside analogues. Lancet 2008;371:1391-2. [Ref.ID 82732]
12.Tiene citas relacionadas Cita con resumen
Cockburn S. Exceptional responses or TRIPS over red tape?. Lancet 2006;368:1063-4. [Ref.ID 78146]
13. Cita con resumen
Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368:505-10. [Ref.ID 77659]
14. Cita con resumen
Simon V, Ho DD, Karim QA. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006;368:489-504. [Ref.ID 77658]
15.Tiene citas relacionadas Cita con resumen
Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholié S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X, for the Trivacan ANR 1269 trial group. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial . Lancet 2006;367:1981-9. [Ref.ID 77234]
16.Tiene citas relacionadas Cita con resumen
Deeks SG. The risk of treatment versus the risk of HIV replication. Lancet 2006;367:1955-6. [Ref.ID 77229]
17. Cita con resumen
Anónimo. Indian groups oppose GSK's Combivir patent. Scrip 2006;3146:16. [Ref.ID 76592]
20. Cita con resumen
Anónimo. GSK surges ahead in 2005, but cautious on 2006. Scrip 2006;3131:8. [Ref.ID 76189]
Seleccionar todas
 1 a 20 de 84 siguiente >>